To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Imbruvica to treat chronic GvHD

FDA approved Imbruvica ibrutinib (PCI-32765) from AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) to treat adults

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE